Results 111 to 120 of about 27,891 (313)

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice

Frontiers in Pharmacology
BackgroundThe purpose of this study was to explore how semaglutide, a GLP-1RA, regulates serum metabolism and gut microbiota to improve obesity in mice and whether fecal microbiota transplantation (FMT) can transmit the beneficial effects of semaglutide ...
Luyan Sun, Bingqing Shang, Suyuan Lv, Guolong Liu, Qiu Wu, Yue Geng   +5 more
doaj   +1 more source

White Adipose Tissue Browning and Cross Talk With Metabolic Diseases and Tumors: From Molecular Mechanisms to Clinical Translation

Med Research, EarlyView.
White adipose tissue undergoes browning under endogenous and exogenous stimuli, primarily regulated by core molecules such as PRDM16 and UCP1. It exhibits a double‐edged sword effect in metabolic diseases and tumors: while mitigating metabolic disease impacts and suppressing early‐stage tumors through nutritional competition, it may accelerate cachexia
Yingjiao Wang, Diyuan Zhang, Yuqin Zhou, Ling Qian, Yan Wang, Lei Peng, Min Zhao, Hao Tian, Zhenyu Wu, Aiqi Tang, Minghao Sun, Yi Zhang, Xiaowei Qi   +12 more
wiley   +1 more source

Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial

BMJ Open Diabetes Research & Care
Introduction This study evaluated the long-term effectiveness of once-weekly subcutaneous semaglutide versus alternative treatment in adults with type 2 diabetes (T2D) in routine clinical practice.Research design and methods The SEmaglutide PRAgmatic ...
John B Buse, Helene Nordahl Christensen, Brian J Harty, Vincent J Willey, Mark J Cziraky, Simon Skibsted   +5 more
doaj   +1 more source

Diabetic Peripheral Neuropathy: Molecular Staging, Risk Factors, Therapeutics, and Emerging Trends

Med Research, EarlyView.
The heterogeneous landscape of DPN can be unified through a tripartite pathogenic model encompassing progressive stages of metabolic dysregulation, chronic inflammation, and overt neuronal damage. Within this framework, six clinical subtypes were identified, namely, hyperglycemia‐driven, dyslipidemia‐driven, inflammation‐driven, dysvascularity‐driven ...
Xiaofeng Dai, Mingze Tang
wiley   +1 more source

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Nature Medicine
The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes.
H. Colhoun, I. Lingvay, Paul M. Brown, J. Deanfield, K. Brown-Frandsen, S. Kahn, Jorge Plutzky, K. Node, Alexander Parkhomenko, L. Rydén, J. P. Wilding, J. Mann, K. Tuttle, T. Idorn, Naveen Rathor, M. Lincoff   +15 more
semanticscholar   +1 more source

Endoscopic small bowel therapies for type 2 diabetes

Nutrition in Clinical Practice, EarlyView.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel, Zehra Naseem, Prisha Gattu, Stephen Firkins, Roberto Simons‐Linares   +4 more
wiley   +1 more source

Beyond GLP‐1: The Cardiometabolic Potential of Dual GLP‐1/GIP Receptor Agonists

iNew Medicine, EarlyView.
Chao Xue
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia

Saudi Pharmaceutical Journal
Introduction: Semaglutide, a Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA), is often prescribed for managing type 2 diabetes, particularly in cases unresponsive to other hypoglycemic agents.
Yazed AlRuthia, Khaled Hani Aburisheh, Sondus Ata, Raghad Bin Salleeh, Shahad B. Alqudhibi, Raghad B. Alqudhibi, Ziad Alkraidis, Hala Humood Alkhalaf, Abdulrahman Abdullah Almogirah, Muhammad Mujammami, Reem Al Khalifah   +10 more
doaj   +1 more source